Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 1 year ago Drug news

FDA approves Raindrop Near Vision Inlay implant for presbyopia- Revision Optics

The FDA has approved the Raindrop Near Vision Inlay, from Revision Optics, a device implanted in the cornea (the clear,...

Added 2 years ago Drug news

FDA approves iDesign Advanced WaveScan Studioaberrometer for LASIK procedures- Abbott

Abbott has announced the FDA approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the...

Added 2 years ago Drug news

FDA approves BrainPort V100 device to orientate blind people- Wicab Inc.

The FDA has allowed marketing of a new device BrainPort V100 from Wicab Inc.,that when used along with other supportive...

Search all news articles for Blindness and vision defects
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Journal articles

Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.

Tasimelteon (Hetlioz(®)) is a dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) (free-running disorder).

Added 1 month ago

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

Background: Most totally blind people have non-24-hour sleep–wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker.

Added 2 years ago

Subretinal Visual Implant Alpha IMS - Clinical trial interim report.

A subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29 blind participants with outer retinal...

Added 2 years ago

Search all journal articles for Blindness and vision defects
 
Vincent de Luise

Vincent de Luise MD FACS is assistant clinical professor of ophthalmology at Yale University School of Medicine, and adjunct clinical assistant professor of ophthalmology at Weill Cornell Medical College, where he is also on the Music and Medicine Initiative. Dr de Luise is physician ... Read more

The End of Sight at the End of Life

I presented this talk, "The End of Sight at the End of Life," on  4/4/2013 at a Harvard University  "Think Tank" on Health and Aging. The two-day conference, held at the Charles Hotel in Cambridge, Massachusetts, brought together prominent scholars from the Harvard School of Public Health as well as global experts in economics, health care policy and longevity, for a fascinating and thought-provoking colloquium on the demographics and consequences of aging in all societies.

CME

Hallucinations - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Amblyopia

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Practice Pointer: How to assess eyes and vision in infants and preschool children

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
89
Search all CME for Blindness and vision defects